These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 31079056)
21. Topical Dexamethasone as an Adjuvant to Mineralocorticoid Receptor Antagonists for the Treatment of Recalcitrant Central Serous Chorioretinopathy. Wong A; Zhu D; Li AS; Lee JG; Ferrone PJ Ophthalmic Surg Lasers Imaging Retina; 2022 Dec; 53(12):659-665. PubMed ID: 36547963 [TBL] [Abstract][Full Text] [Related]
22. Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy. Fasler K; Gunzinger JM; Barthelmes D; Zweifel SA Front Pharmacol; 2021; 12():675295. PubMed ID: 34040534 [No Abstract] [Full Text] [Related]
23. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Pichi F; Carrai P; Ciardella A; Behar-Cohen F; Nucci P; Int Ophthalmol; 2017 Oct; 37(5):1115-1125. PubMed ID: 27757733 [TBL] [Abstract][Full Text] [Related]
24. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. Sun X; Shuai Y; Fang W; Li J; Ge W; Yuan S; Liu Q Br J Ophthalmol; 2018 Aug; 102(8):1060-1065. PubMed ID: 29089356 [TBL] [Abstract][Full Text] [Related]
25. Optical Coherence Tomography Parameters as Predictors of Treatment Response to Eplerenone in Central Serous Chorioretinopathy. Borrelli E; Zuccaro B; Zucchiatti I; Parravano M; Querques L; Costanzo E; Sacconi R; Prascina F; Scarinci F; Bandello F; Querques G J Clin Med; 2019 Aug; 8(9):. PubMed ID: 31443376 [No Abstract] [Full Text] [Related]
26. Should We Stop Treating Patients With Eplerenone for Chronic CSCR? Commentary on the VICI Trial. Daugirdas SP; Bheemidi AR; Singh RP Ophthalmic Surg Lasers Imaging Retina; 2021 Jun; 52(6):308-310. PubMed ID: 34185584 [TBL] [Abstract][Full Text] [Related]
27. The use of mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy. Pociej-Marciak W; Karska-Basta I; Ozog-Baran J; Kubicka-Trzaska A; Filemonowicz-Skoczek A; Romanowska-Dixon B Klin Oczna; 2016 Aug; 118(1):48-54. PubMed ID: 29715409 [TBL] [Abstract][Full Text] [Related]
28. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy. Gawęcki M; Jaszczuk-Maciejewska A; Jurska-Jaśko A; Kneba M; Grzybowski A BMC Ophthalmol; 2019 Jul; 19(1):160. PubMed ID: 31345183 [TBL] [Abstract][Full Text] [Related]
30. Low-dose methotrexate for the treatment of chronic central serous chorioretinopathy: a retrospective analysis. Kurup SK; Oliver A; Emanuelli A; Hau V; Callanan D Retina; 2012; 32(10):2096-101. PubMed ID: 22718154 [TBL] [Abstract][Full Text] [Related]
31. Response of central serous chorioretinopathy evaluated by multimodal retinal imaging. Sacconi R; Baldin G; Carnevali A; Querques L; Rabiolo A; Marchini G; Bandello F; Querques G Eye (Lond); 2018 Apr; 32(4):734-742. PubMed ID: 29303152 [TBL] [Abstract][Full Text] [Related]
32. Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence. Bousquet E; Zhao M; Daruich A; Behar-Cohen F Exp Eye Res; 2019 Oct; 187():107754. PubMed ID: 31401003 [TBL] [Abstract][Full Text] [Related]
33. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy. Lai FH; Ng DS; Bakthavatsalam M; Chan VC; Young AL; Luk FO; Tsang CW; Brelén ME Am J Ophthalmol; 2016 Oct; 170():91-99. PubMed ID: 27519561 [TBL] [Abstract][Full Text] [Related]
34. SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY. Bousquet E; Beydoun T; Rothschild PR; Bergin C; Zhao M; Batista R; Brandely ML; Couraud B; Farman N; Gaudric A; Chast F; Behar-Cohen F Retina; 2015 Dec; 35(12):2505-15. PubMed ID: 26017871 [TBL] [Abstract][Full Text] [Related]
35. Eplerenone for the Treatment of Chronic Recurrent Chorioretinopathy Centralis Serosa. Herrmann LM; Matthé E; Sandner D; Wittig D Klin Monbl Augenheilkd; 2024 Sep; 241(9):1039-1043. PubMed ID: 37669743 [TBL] [Abstract][Full Text] [Related]
36. Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy. Yang D; Eliott D Semin Ophthalmol; 2017; 32(1):36-42. PubMed ID: 27929707 [TBL] [Abstract][Full Text] [Related]
37. Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: case report. Gruszka A Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1369-73. PubMed ID: 23740451 [TBL] [Abstract][Full Text] [Related]
38. Subthreshold laser compared to oral spironolactone for the treatment of chronic central serous chorioretinopathy: a retrospective study. Mercuri S; D'Alterio FM; Gallo B; Raslan W; Gupta A; Khairat N; Corazza P; Younis S Int Ophthalmol; 2024 Mar; 44(1):131. PubMed ID: 38478131 [TBL] [Abstract][Full Text] [Related]
39. COMPARISON OF SHORT-TERM EFFICACY BETWEEN ORAL SPIRONOLACTONE TREATMENT AND PHOTODYNAMIC THERAPY FOR THE TREATMENT OF NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. Lee JH; Lee SC; Kim H; Lee CS Retina; 2019 Jan; 39(1):127-133. PubMed ID: 29095358 [TBL] [Abstract][Full Text] [Related]